{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000232","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.660857+00:00","generated_at":"2026-06-20T20:18:52.369547+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulmatrix reports positive Phase 1 results for inhaled migraine drug PUR3100; Tmax 5 min, fewer GI side effects","bullets":["PUR3100 was safe and well-tolerated; no emesis in any dose group; lower nausea incidence vs IV DHE.","Peak plasma concentration (Cmax) reached targeted therapeutic range at all three doses; Tmax of 5 minutes.","Phase 2 dose selection underway; FDA meeting requested in January 2023.","Study enrolled 26 healthy subjects in double-dummy, double-blinded design comparing inhaled PUR3100 vs IV DHE."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000232","json":"https://secwatch.observer/filing/0001493152-23-000232.json","markdown":"https://secwatch.observer/filing/0001493152-23-000232.md","text":"https://secwatch.observer/filing/0001493152-23-000232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223000232/0001493152-23-000232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223000232/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:18:52.369547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}